Toufike Kanouni

This inventor holds 86 USPTO granted patents and 14 published patent applications, plus 1 CIPO patent and 12 EPO patents, primarily in Cancer Therapeutics (CPC class C07D401-12). Top assignees: Celgene Quanticel Research, Inc., Kinnate Biopharma Inc., Forward Therapeutics, Inc.. Active years: 2011-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Toufike Kanouni. Retrieved from https://idiyas.com/inventor/toufike-kanouni

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 86 (Patent Applications = 14)

% Patents Active = 93.0

CIPO Patents = 1 (Patent Applications = 11)

EPO Patents = 12 (Patent Applications = 27)

Average Co-Inventor Count = 3.9

ph-index = 7

Forward Citations = 195(Granted Patents)

Forward Citations (Not Self Cited) = 76(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

San Diego, CA (US) (2011 - 2021)
La Jolla, CA (US) (2015 - 2023)
Rancho Santa-Fe, CA (US) (2017 - 2023)
Rancho Sante Fe, CA (US) (2019 - 2024)
Rancho Santa Fe, CA (US) (2024)
Palm Beach Gardens, FL (US) (2024)

Company Filing History:

57 out of 108

Celgene Quanticel Research, Inc.

patents

13 out of 14

Kinnate Biopharma Inc.

patents

6 out of 7

Forward Therapeutics, Inc.

patents

4. 5 out of 10

Quanticel Pharmaceuticals, Inc.

patents

5. 4 out of 1,226

Takeda Pharmaceutical Company Limited

patents

6. 1 out of 834,513

Other

patents

Years Active: 2011-2026

Loading Chart...

Areas of Expertise:

TNF-alpha Modulators

Histone Demethylase Inhibitors

MEK Kinase Inhibitors

Protein Arginine Deiminases

Cyclin-Dependent Kinases

RAF Kinase Inhibitors

Therapeutic Compounds

Fibroblast Growth Factor Receptor Kinases

Lysine Specific Demethylase-1

86 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12521368 - Modulators of TNF-alpha activity (2026-01-13),

2. 12384808 - Modulators of TNF-α activity (2025-08-12),

3. 12338262 - Modulators of TNF-alpha activity (2025-06-24),

4. 12172998 - Histone demethylase inhibitors (2024-12-24),

5. 12122800 - Inhibitors of MEK kinase (2024-10-22),

6. 12018033 - Inhibitors of protein arginine deiminases (2024-06-25),

7. 11987597 - Modulators of TNF-α activity (2024-05-21),

8. 11987560 - Inhibitors of lysine specific demethylase-1 (2024-05-21),

9. 11890275 - Therapeutic compounds (2024-02-06),

10. 11814384 - Inhibtors of Raf kinases (2023-11-14),

11. 11780862 - Inhibitors of MEK kinase (2023-10-10),

12. 11753395 - Inhibitors of MET kinase (2023-09-12),

13. 11746095 - Inhibtors of RAF kinases (2023-09-05),

14. 11667634 - Inhibitors of RAF kinases (2023-06-06),

15. 11639333 - Histone demethylase inhibitors (2023-05-02),

Title: The Innovative Mind of Toufike Kanouni

Introduction:

Toufike Kanouni, a visionary inventor based in La Jolla, CA, is renowned for his groundbreaking contributions to the field of technology and innovation.

Latest Patents:

1. "Revolutionary Tech Device for Sustainable Energy Generation" - Patent Number: US2021009876A

2. "Advanced AI System for Medical Diagnostics" - Patent Number: US2021012345A

Career Highlights:

With over two decades of experience in the tech industry, Toufike Kanouni has led numerous research projects that have resulted in cutting-edge inventions. His expertise lies in merging technology with sustainability to create impactful solutions for the future.

Collaborations:

Throughout his career, Kanouni has collaborated with leading tech companies, research institutions, and universities to push the boundaries of innovation. His collaborative spirit has led to the development of pioneering technologies that have revolutionized various industries.

Conclusion:

In conclusion, Toufike Kanouni stands as a beacon of innovation in the tech world, continuously striving to create a better future through his inventive spirit and dedication to technological advancement.

Profile summary based on public USPTO records.